Skip to main content
SpringerLink
Log in

Selected breast cancer highlights from the ASCO 2012

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

The abstracts are a selection of clinically relevant papers presented at the American Society of Clinical Oncology (ASCO) 2012. The results of the EMILIA study were a milestone presented at the meeting. A total of 991 patients with metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer had been pretreated with a taxane and trastuzumab. They were randomized into two groups: Trastuzumab emtansine conjugate (T-DM1) or capecitabine-lapatinib. Significant differences were found with regard to progression-free survival and the two-year overall survival. Another study analyzed the relevance of the hormone-receptor (HR) status for the prognosis of patients with operable HER2-overexpressing breast cancer. A significant difference in the risk of the development of brain metastases was found depending on the HR status. In the MA.27 study, patients received adjuvant therapy with aromatase inhibitors. A significant proportion of cases reported therapy of osteoporosis, mainly with bisphosphonates. Osteoporosis therapy influenced recurrence-free survival. In another study, the prognostic influence of Ki-67 was evaluated before and after neoadjuvant chemotherapy with TAC (docetaxel/doxorubicin/cyclophosphamide). A metaanalysis analyzed the possible discordance between the HR status and the HER2 status in the primary tumor as compared to metastasis in 2,806 breast cancer patients. The estrogen-receptor (ER)-, and the progesterone-receptor (PR) status as well as the HER2 status changed in a significant proportion of cases. Parenteral nutrition in 129 terminal oncological patients with progressive cancer was investigated within a randomized placebo-controlled trial. They either received one liter of 0.9 % physiological saline subcutaneously or placebo. Survival, symptoms of dehydration, and quality of life were analyzed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Blackwell K, Miles D, Gianni L, Krop I, Welslau M, Baselga J, Pegram M, Oh D, Dieras V, Olsen S, Fang L, Lu M, Guardino E, Verma S. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. J Clin Oncol. 2012;30(Suppl) LBA 1

  2. Vaz Duarte L et al. Impact of hormone receptor status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients with human epidermal growth factor receptor-2 positive (HER2) breast cancer in the National comprehensive cancer network (NCCN). J Clin Oncol. 2012;30 (Suppl) Abstr. 599

    Google Scholar 

  3. Shepherd E, Chapman J, Ali S, Zhu L, Leitzel K, Goss P, Lipton A. Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrazole. NCIC CTG MA.27. J Clin Oncol. 2012;30(Suppl)Abstr.501

    Google Scholar 

  4. Von Minckwitz G, Mueller B, Blohmer J, Kaufmann M, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Ruediger T, Erbstoesser E, Loibl S, Denkert C. Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. J Clin Oncol. 2012;30(Suppl)Abstr.1023

    Google Scholar 

  5. Aurilio G, Disalvatore D, Bagnardi V, Munzone E, Adamoli L, Curigliano G, Pruneri G, Sciandivasci A, De Vita F, Goldhirsch A, Nole F. A meta-analysis of receptor status discordance between primary breast cancer and metastases. J Clin Oncol. 2012;30(Suppl):546

    Google Scholar 

  6. Dalal S, Hui D, Torres-Vigil I, Palmer L, Allo J, Frisbee-Hume S, Tarleton K, Bruera E. Parenteral hydration in advanced cancer patients: a multi-center, double-blind, placebo-controlled randomized trial. J Clin Oncol. 2012;30(Suppl)Abstr.9025.

    Google Scholar 

Download references

Conflict of interest

The authors declare that there is no actual or potential conflict of interest in relation to this article.

Author information

Authors and Affiliations

  1. Clinical Department, University Hospital for Gynecology, Auenbruggerplatz 14, 8036, Graz, Austria

    Edgar Petru &  Eva-Christine Weiss

Authors
  1. Edgar Petru
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eva-Christine Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edgar Petru.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Petru, E., Weiss, EC. Selected breast cancer highlights from the ASCO 2012. memo 6, 29–31 (2013). https://doi.org/10.1007/s12254-012-0067-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-012-0067-3

Keywords

Search

Navigation